CN102178680A - Long-acting and high-content Huperzine paster and preparation method thereof - Google Patents
Long-acting and high-content Huperzine paster and preparation method thereof Download PDFInfo
- Publication number
- CN102178680A CN102178680A CN 201110104751 CN201110104751A CN102178680A CN 102178680 A CN102178680 A CN 102178680A CN 201110104751 CN201110104751 CN 201110104751 CN 201110104751 A CN201110104751 A CN 201110104751A CN 102178680 A CN102178680 A CN 102178680A
- Authority
- CN
- China
- Prior art keywords
- paster
- huperzine
- preparation
- lecithin
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a Huperzine paster and a preparation method thereof. The Huperzine paster is a flaky transdermal absorption preparation formed by overlapping an adhesive layer, a medicament substrate and a supporting layer, wherein the medicament layer comprises the Huperzine, pharmaceutically acceptable salt, lecithin and paster conventional auxiliary materials; the weight ratio of the lecithin to the Huperzine is 1:(0.4-2.5); the medicament substrate is coated on the adhesive layer and the coating thickness is 0.35 to 0.6 mm; and the pH value of the paster is between 5.0 and 8.0. The Huperzine paster is administrated through a transdermal penetration route, overcomes the defects of the original Huperzine paster, can be absorbed in a human body quickly, has long-term effectiveness and high content, solves the problem of high medicament residual ratio of the common paster, and is used for treating or preventing nerve system diseases such as Parkinson's disease, senile dementia, depression and the like.
Description
(1) technical field: the present invention relates to a kind of external used medicine paster, be specifically related to a kind of huperzine A paster and preparation method thereof.
(2) background technology: at present, whole world alzheimer disease number of the infected is up to 2,000 ten thousand.In the U.S., surpass 4,000,000 people and suffer from this disease, become the fourth-largest killer who is only second to cardiovascular diseases, cancer and apoplexy.Country's " 95 " brainstorm subject group has been finished the large sample Epidemiological study that China carries out dementia first in 2002.Investigation finds that China has 8,811 10,000 65 years old and above old men now, and dull-witted number of patients surpasses 6,000,000.A large amount of senile dementia patients brings white elephant for household, society.
In recent years, medical circle is paid attention to day by day to the treatment of alzheimer disease, and Drug therapy has had very great development.Cholinesterase inhibitor is acknowledged as topmost treatment alzheimer disease medicine.Huperzine A belongs to the high selectivity cholinesterase inhibitor, has the advantages that to penetrate blood brain barrier.Studies have shown that the mechanism of action of huperzine A system is by suppressing acetylcholine esterase active in the brain, improve levels of acetylcholine and play a role.Its significant advantage is that cerebral cortex relevant with memory and the inhibition acetylcholine esterase effect of Hippocampus obviously are better than other brain district, persistent period was 6 hours, and can obviously promote the cholinergic transmission at neuromuscular junction place, its action intensity is greater than similar medicine.Huperzine A all has tangible effect to improving person in middle and old age's hypomnesis and patients with Alzheimer disease memory ability and cognitive competence, is current treatment degenerative brain disorder one of the most effective medicine.Simultaneously, huperzine A also has better effects to improving adolescence student memory and school grade.
Because alzheimer disease needs long-term prescription; and according to patient's own characteristic; forget the clothes or the thing that misses even take medicine more through regular meeting, thus the untoward reaction that causes the uncontrollable or long-term drug overdose of the state of an illness to cause, therefore novel very suitable this class of huperzine A paster patient's medication.
The correlational study of domestic existing huperzine A paster, a kind of huperzine A percutaneous absorption patch is disclosed as Chinese patent CN95111588, it shows good when the animal Transdermal absorption is tested after transdermal test in vitro absorption and unhairing, but can't reach re-set target in the actual human body test, infiltration rate is slower, long to peak time, not high because of drug loading simultaneously, its drug effect was only kept 3-4 days, show using the saturating sheet paster in back to detect, the remaining rate height of medicine, drug waste is bigger, also causes using dosage inaccurate simultaneously.
(3) summary of the invention: task of the present invention is the defective that overcomes existing huperzine A paster, provide a kind of at human body fast Absorption, long-acting, high-load huperzine A paster and preparation method thereof, this paster has solved the high problem of the remaining rate of medicine of common paster simultaneously.
One of task of the present invention provides a kind of to human body safety, fast Absorption, long-acting, high-load huperzine A paster, form by adhesion coating, drug matrices and supporting layer, drug matrices is coated on the adhesion coating, it is characterized in that: medicine layer comprises huperzine A and pharmaceutically acceptable salt, lecithin and conventional adjuvant, and wherein the part by weight of lecithin and huperzine A is 1: 0.4-2.5.
The pH value of paster of the present invention is controlled between the 5.0-8.0.
Preferred dose is that every square centimeter contains huperzine A 0.1-1.0mg in the huperzine A paster of the present invention's preparation.
The present invention also provides a kind of preparation method of huperzine A paster, comprises the preparation drug matrices, and drug matrices is applied on the adhesion coating, and drying is covered with supporting layer, and step is as follows:
(1) gets recipe quantity lecithin, huperzine A mix homogeneously;
(2) alcoholic solution of adding an amount of 80% in mixture is regulated pH value to 1.0-3.0 with hydrochloric acid, and vibration is dissolved mixture fully, obtains lysate;
(3) in above-mentioned lysate, add the conventional adjuvant of paster, regulate pH value to 5.0-8.0 with buffer; Wherein buffer is selected from a kind of in the phosphate buffer, Borax-calcium chloride buffer, ammonia-chloride buffer solution of pH value 7.0-8.5;
(4) with the above-mentioned solution that regulates, be dried to relative density on the following vibration of 85 ℃ conditions limit and be 1.10～1.15 thick liquid, it is drug matrices, then drug matrices is applied on the adhesion coating of paster, thickness is between the 0.35-0.6 millimeter, drying is covered with supporting layer, obtains the huperzine A paster after shearing.
Huperzine A is a kind of alkaloid, and itself has alkalescence, but because huperzine A dissolubility in water is very little, need in acid solution, dissolve, and the paster that low pH value is made not only has stimulation to human body skin, and can cause infiltration rate to slow down, and absorbtivity reduces.
Huperzine A belongs to liposoluble substance, high spot reviews of the present invention the liposoluble substance influence saturating to the medicine percutaneous, screening obtains making huperzine A to produce the lecithin of better transdermal penetration, optimizing prescriptions, and huperzine A is with after lecithin fully mixes, find by human trial, its skin absorbs speed is obviously accelerated, and its metabolism time lengthening in vivo is more suitable for the long-acting treatment in paster simultaneously, solve the high problem of the remaining rate of medicine of common paster simultaneously, obtained remarkable result.
This paster is used for the treatment of or prevents nervous system disease, as parkinson disease, senile dementia, depression etc.
(4) description of drawings:
Fig. 1 is two kinds of different huperzine A paster human bioavailability comparison diagrams in the embodiment of the invention 7, and two kinds of different huperzine A pasters are respectively by the huperzine A paster of CN95111588 embodiment 1 preparation and the huperzine A paster for preparing by the embodiment of the invention 1.
(5) specific embodiment: the following examples are used to further specify and describe the present invention, but and do not mean that the present invention only limits to this.
Embodiment 1: the preparation of huperzine A paster 1
Prescription:
Preparation method comprises the preparation drug matrices, and drug matrices is applied on the adhesion coating, and drying is covered with supporting layer, shears, and obtains the huperzine A paster, and step is as follows:
I, take by weighing recipe quantity huperzine A and lecithin, mix homogeneously;
II, add an amount of 80% alcoholic solution in mixture, regulate pH value to the 1.0-3.0 with hydrochloric acid, vibration is dissolved mixture fully;
III, in above-mentioned lysate, add adjuvant: polyacrylate (national of the United States's starch company, the 387-2287 type) 170g, laurocapram 4g, lauric acid 7g, propylene glycol 17g, and regulate pH value to 5.0-8.0 with the ammonia of pH8.5-chloride buffer solution, also can adopt the buffer of other pH value 7.0-8.5 to regulate pH value;
IV, with the above-mentioned solution that regulates, (85 ℃ of water-baths, prompt experimental apparatus Manufacturing Co., Ltd in HH-S2 thermostatic type Changzhou) is dried to relative density in while vibrating and is 1.10～1.15 thick liquid, it is drug matrices, use automatic coating machine (the triumphant company of the Shanghai iron of fine quality then, the TB-04 type) above-mentioned drug matrices is coated on the adhesion coating (siliconised paper), coating thickness is 0.5 millimeter;
V, 60 ℃ of oven dry were covered with supporting layer after 5 minutes, and are promptly transferable, again that paster is die-cut or cut into last thin slice, obtain huperzine A paster 1, and recording huperzine A content is every square centimeter of 300 μ g.
Embodiment 2: the preparation of huperzine A paster 2
Prescription:
Preparation method is with embodiment 1, and the coating thickness of huperzine A paster 2 is 0.6 millimeter, and recording huperzine A content in the product is every square centimeter of 900 μ g.
Embodiment 3: the preparation of huperzine A paster 3
Prescription:
Preparation method is with embodiment 1, and the coating thickness of huperzine A paster 3 is 0.35 millimeter, and recording huperzine A content in the product is every square centimeter of 100 μ g.
Embodiment 4: the preparation of huperzine A paster 4
Prescription:
Preparation method is with embodiment 1, and the coating thickness of huperzine A paster 4 is 0.45 millimeter, and recording huperzine A content in the product is every square centimeter of 350 μ g.
Embodiment 5: animal pharmacokinetics is measured
I, instrument: Shimadzu LC-10A high performance liquid chromatograph, SPD-10A UV-detector, C-R6A data process machine.Shim-Pack CLC-ODS post (6.0X150mm)
II, method
A, unhairing: use depilatory (6%Na in the domesticated dog back
2SO
3) take off the skin of two 4X6CM2 sizes, and clean up with clear water;
B, paster: paste the huperzine A paster in domesticated dog depilation place, and behind 120h, take off paster;
C, get blood: after medication, got domesticated dog femoral vein blood in 2,4,6,8,10,24,32,48,56,72,84,96,108,120,132,148,150 hours;
D, detection:, detect huperzine content in the blood with the high performance liquid chromatograph ultraviolet absorption method with the U.S. hot internal standard method of diindyl diindyl.
III, result
Prepare the huperzine A paster respectively by the CN95111588 embodiment 1 and the embodiment of the invention 1, be affixed on domesticated dog unhairing place, wherein contained huperzine A total content is 4mg in the paster, and the medicine of respectively finishing 6 domesticated dogs is for mensuration, average result such as following table:
IV, analysis
With the huperzine A paster contrast of CN95111588 preparation, huperzine A paster peak time on domesticated dog of the present invention's preparation is faster, and the effective drug duration prolongation, and drug release is more mild.
Embodiment 6: the healthy human body tolerance test
A, test routine number: " chemicals CLINICAL PHARMACOKINETIS STUDY ON technological guidance principle " (second original text) announced according to national drug food Surveillance Authority in 2004, the huperzine A paster is taked dosage escalation regimens, designing maximum dosage is 12mg/ people/day, and the single-dose tolerance test is totally 28 people.
B, medication: external.Be affixed on cleaning drying, not damaged chest (under the clavicle) skin immediately after removing the protective layer on the paster.
C, untoward reaction are observed: mainly observe uncomfortable main suit, the medication local response is often seen biochemical indicator.
D, result:
According to the standard that work out at Ministry of Public Health adverse drug reaction supervision center, assessment is made in the association that may exist between adverse events and the test medication by " certainly, probably, possible, suspicious, impossible " Pyatyi classification method.The huperzine A paster of the embodiment of the invention 1 preparation, test through 28 experimenters, in human tolerance test, find to reach the adverse events of above rank (comprise certainly, probably, may), illustrate that huperzine A paster prepared in accordance with the present invention safety is good with this product.
Embodiment 7: the test of healthy human body single pharmacokinetics
Carried out the pharmacokinetics test according to " chemical drugs CLINICAL PHARMACOKINETIS STUDY ON guideline ".
A, administering mode
Huperzine A paster (containing huperzine A 10mg) is affixed on that cleaning is dry, take off not damaged skin of chest (under the clavicle) to the 8th day morning.
B, sampled point
Adopted experimenter's blood sample before the administration and after the administration in 8,16,24,32,40,48,60,72,84,96,108,120,132,144,156,168,192,216,240 hours.
C, assay method: LC-MS-MS (liquid phase tandem mass spectrum, tinidazole internal standard method)
Reagent:
Huperzine A reference substance: provide by Nat'l Pharmaceutical ﹠ Biological Products Control Institute;
Tinidazole reference substance: provide by Nat'l Pharmaceutical ﹠ Biological Products Control Institute;
Methanol: chromatographically pure, Merck Company;
Acetonitrile: chromatographically pure, Merck Company;
Formic acid: chromatographically pure, Tedia Company Inc..
Instrument:
Prunus mume (sieb.) sieb.et zucc. Teller-Tuo benefit AE240 electronic balance (Shanghai Mettler-Toledo, Inc.);
API4000LC/MS/MS combined instrument (u.s.a. applied biosystem company), chromatographic work station: Analyst 1.4.2;
Prunus mume (sieb.) sieb.et zucc. Teller-Tuo benefit Delta320A/CPH counts (Shanghai Mettler-Toledo, Inc.);
Biofuge PrimoR high-speed refrigerated centrifuge (German Heraeus company);
Millipore Drict-Q5 ultrapure water machine (French Millipore company).
D, result
With LC-MS-MS (liquid phase tandem mass spectrum, tinidazole internal standard method) assay determination according to the human bioavailability of the human bioavailability of the huperzine A paster of CN95111588 embodiment 1 preparation and the huperzine A paster by the embodiment of the invention 1 preparation.The results are shown in following table:
Fig. 1 is seen in contrast more intuitively.
Above-mentioned data show, in the human body experimenter, the huperzine A paster that the huperzine A paster drug releasing rate of the present invention's preparation obviously prepares faster than CN95111588, and peak time is also faster, drug level with hold time more lasting, slow release effect is more obvious, in the medication concentration of can both remaining valid in the process in 7 days, is more suitable for long-time application.
Embodiment 8: paster medicine residue detection
Huperzine A paster after embodiment 6 uses is carried out the medicine residue detection, the result is respectively 3.23mg and 3.11mg by the last medicine remnants of huperzine A paster of CN95111588 preparation, and is respectively 1.87mg and 1.45mg by the last medicine remnants of huperzine A paster of the present invention's preparation.Explanation is by easier human body skin, the drug utilization Du Genggao of seeing through of the huperzine A paster of the present invention's preparation.
Claims (4)
1. huperzine A paster, form by adhesion coating, drug matrices and supporting layer, drug matrices is coated on the adhesion coating, it is characterized in that: medicine layer comprises huperzine A and pharmaceutically acceptable salt, lecithin and conventional paster adjuvant, and the part by weight of lecithin and huperzine A is 1: 0.4-2.5; The pH value of paster is controlled between the 5.0-8.0.
2. huperzine A paster according to claim 1 is characterized in that every square centimeter contains the 0.1-1mg huperzine A in the described paster.
3. the preparation method of huperzine A paster according to claim 1 and 2 is characterized in that through following step:
(1) will write out a prescription lecithin, huperzine A mix homogeneously;
(2) alcoholic solution of adding an amount of 80% in mixture is regulated pH value to 1.0-3.0 with hydrochloric acid, and vibration is dissolved mixture fully, obtains lysate;
(3) in above-mentioned lysate, add conventional paster adjuvant, regulate pH value to 5.0-8.0 with buffer;
(4) with the above-mentioned solution that regulates, be dried to relative density on the following vibration of 85 ℃ conditions limit and be 1.10～1.15 thick liquid, promptly drug matrices is applied to drug matrices on the adhesion coating of paster, and thickness is the 0.35-0.6 millimeter, is covered with supporting layer.
4. according to the preparation method of the described huperzine A paster of claim 3, it is characterized in that described buffer is a kind of in phosphate buffer, Borax-calcium chloride buffer, the ammonia-chloride buffer solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110104751A CN102178680B (en) | 2011-04-24 | 2011-04-24 | Long-acting and high-content Huperzine plaster and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110104751A CN102178680B (en) | 2011-04-24 | 2011-04-24 | Long-acting and high-content Huperzine plaster and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102178680A true CN102178680A (en) | 2011-09-14 |
| CN102178680B CN102178680B (en) | 2012-09-05 |
Family
ID=44565087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110104751A Active CN102178680B (en) | 2011-04-24 | 2011-04-24 | Long-acting and high-content Huperzine plaster and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102178680B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103980198A (en) * | 2013-02-08 | 2014-08-13 | 复旦大学 | Alkaloid Casuarinine H and use thereof in preparation of medicines for treating neurodegenerative diseases |
| CN113318096A (en) * | 2021-06-23 | 2021-08-31 | 烟台大学 | Transdermal therapeutic system of huperzine A and its derivatives |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1111987A (en) * | 1995-04-10 | 1995-11-22 | 浙江省医学科学院 | Transcutaneous huperzing sticker |
| US6352715B1 (en) * | 1998-02-19 | 2002-03-05 | Sagittarius Life Science Corp | Transdermal rate-controlled delivery of Huperzine A for treatment of alzheimer's disease |
| CN1450882A (en) * | 1999-11-04 | 2003-10-22 | 美国爱科赛尔制药有限公司 | Transdermal administration of huperzine |
| CN1761452A (en) * | 2003-03-14 | 2006-04-19 | 德比欧药物研究有限公司 | Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders |
| CN1946377A (en) * | 2004-04-22 | 2007-04-11 | 萨诺化学药物股份公司 | Cholinesterase inhibitors in liposomes and their production and use |
-
2011
- 2011-04-24 CN CN201110104751A patent/CN102178680B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1111987A (en) * | 1995-04-10 | 1995-11-22 | 浙江省医学科学院 | Transcutaneous huperzing sticker |
| US6352715B1 (en) * | 1998-02-19 | 2002-03-05 | Sagittarius Life Science Corp | Transdermal rate-controlled delivery of Huperzine A for treatment of alzheimer's disease |
| CN1450882A (en) * | 1999-11-04 | 2003-10-22 | 美国爱科赛尔制药有限公司 | Transdermal administration of huperzine |
| CN1761452A (en) * | 2003-03-14 | 2006-04-19 | 德比欧药物研究有限公司 | Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders |
| CN1946377A (en) * | 2004-04-22 | 2007-04-11 | 萨诺化学药物股份公司 | Cholinesterase inhibitors in liposomes and their production and use |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103980198A (en) * | 2013-02-08 | 2014-08-13 | 复旦大学 | Alkaloid Casuarinine H and use thereof in preparation of medicines for treating neurodegenerative diseases |
| CN103980198B (en) * | 2013-02-08 | 2016-09-07 | 复旦大学 | Alkaloid Casuarinine H and the purposes in preparation treatment nerve degenerative diseases medicine thereof |
| CN113318096A (en) * | 2021-06-23 | 2021-08-31 | 烟台大学 | Transdermal therapeutic system of huperzine A and its derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102178680B (en) | 2012-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2335012C (en) | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders | |
| AU618949B2 (en) | Phenyl carbamate | |
| Fliegert et al. | The effects of tramadol on static and dynamic pupillometry in healthy subjects—the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status | |
| CN100371714C (en) | Methods and compositions for treatment of central nervous system disorders | |
| CN102178680B (en) | Long-acting and high-content Huperzine plaster and preparation method thereof | |
| Black et al. | N‐methyl‐d‐aspartate‐or glutamate‐mediated toxicity in cultured rat cortical neurons is antagonized by FPL 15896AR | |
| Pittaluga et al. | Activity of putative cognition enhancers in kynurenate test performed with human neocortex slices | |
| CN101390843A (en) | Lovastatin and niacin slow-release tablet and preparation method thereof | |
| Ashford et al. | Advances in Alzheimer therapy: Cholinesterase inhibitors | |
| Böttcher et al. | Compliance testing of patients in ADHD treatment with lisdexamphetamine (Elvanse®) using oral fluid as specimen | |
| Ye et al. | Pharmacokinetics of Huperzine A after transdermal and oral administration in beagle dogs | |
| Aksoy et al. | The suppression of endogenous adrenalin in the prolongation of ketamine anesthesia | |
| Sharma | Studies on adrenocortical carcinoma of rat cyclic nucleotide phosphodiesterase activities | |
| Wang et al. | Mahuannin B an adenylate cyclase inhibitor attenuates hyperhidrosis via suppressing β2-adrenoceptor/cAMP signaling pathway | |
| EP2311463A1 (en) | Analogs of galanthamine and lycoramine as modulators of nicotinic receptors | |
| CN104138384A (en) | Applications of five-ring triterpenoid compounds as oxidized squalene cyclase inhibitors | |
| Song et al. | Central GABAA and GABAB receptor modulation of basal and stress-induced plasma interleukin-6 levels in mice | |
| Norbury et al. | Pharmacokinetics of the new analgesic, meptazinol, after oral and intravenous administration to volunteers | |
| Nah et al. | Effects of ginseng saponin on acute cocaine-induced alterations in evoked dopamine release and uptake in rat brain nucleus accumbens | |
| Li et al. | Interactions between morphine, scopolamine and nicotine: schedule-controlled responding in rats | |
| US8530525B2 (en) | Methods and compositions for protecting and treating neuroinjury | |
| Potter et al. | Alterations in modulation of acetylcholine release following lesion of hippocampal cholinergic neurons with the neurotoxin AF64A | |
| Moradov et al. | Dose-Limiting inhibition of acetylcholinesterase by ladostigil results from the rapid formation and fast hydrolysis of the drug–enzyme complex formed by its major metabolite, R-MCPAI | |
| CN101829068A (en) | Water soluble medicament sustained-release tablets and preparation method thereof | |
| Van Tellingen et al. | A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |